Skip to main content
. 2015 Sep 18;59(10):6017–6025. doi: 10.1128/AAC.00932-15

TABLE 4.

Characterization of novel NS3 R155 and D168 variants derived from isolates from patients in phase 2 studies

GTa NS3 variant No. of samples Mean (range) faldaprevir EC50b fold change relative to baseline
1a R155K + D168E 3 623 (588–680)
D168E 1 24
D168A 1 360
R155S 1 131
1b R155Q + D168N 1 162
R155Q + D168V 1 38
D168Y 1 1,261
a

GT, genotype.

b

EC50, 50% effective concentration.